Disease-Regulated Gene Therapy with Anti-Inflammatory Interleukin-10 Under the Control of the CXCL10 Promoter for the Treatment of Rheumatoid Arthritis.

MLA

Broeren, Mathijs G. A., et al. “Disease-Regulated Gene Therapy with Anti-Inflammatory Interleukin-10 Under the Control of the CXCL10 Promoter for the Treatment of Rheumatoid Arthritis.” Human Gene Therapy, vol. 27, no. 3, Mar. 2016, pp. 244–54. EBSCOhost, https://doi.org/10.1089/hum.2015.127.

APA

Broeren, M. G. A., de Vries, M., Bennink, M. B., Arntz, O. J., Blom, A. B., Koenders, M. I., van Lent, P. L. E. M., van der Kraan, P. M., van den Berg, W. B., & van de Loo, F. A. J. (2016). Disease-Regulated Gene Therapy with Anti-Inflammatory Interleukin-10 Under the Control of the CXCL10 Promoter for the Treatment of Rheumatoid Arthritis. Human Gene Therapy, 27(3), 244–254. https://doi.org/10.1089/hum.2015.127

Chicago

Broeren, Mathijs G A, Marieke de Vries, Miranda B Bennink, Onno J Arntz, Arjen B Blom, Marije I Koenders, Peter L E M van Lent, Peter M van der Kraan, Wim B van den Berg, and Fons A J van de Loo. 2016. “Disease-Regulated Gene Therapy with Anti-Inflammatory Interleukin-10 Under the Control of the CXCL10 Promoter for the Treatment of Rheumatoid Arthritis.” Human Gene Therapy 27 (3): 244–54. doi:10.1089/hum.2015.127.